Coherus Oncology (CHRS) Cash & Equivalents (2012 - 2026)

Coherus Oncology has disclosed Cash & Equivalents across 15 years of filings, most recently posting $115.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $115.2 million, up 39.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.2 million (up 39.83% YoY), and the FY2025 annual result was $88.9 million, down 29.45% from the prior year.
• Cash & Equivalents came in at $115.2 million for Q1 2026 at Coherus Oncology, up from $88.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $325.7 million in Q1 2022 to a low of $16.1 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $103.4 million (2025), against an average of $145.5 million.
• Across the five-year window, Cash & Equivalents plunged 95.04% in 2023 and surged 1509.01% in 2024, its largest moves.
• Coherus Oncology's Cash & Equivalents stood at $63.5 million in 2022, then jumped by 61.91% to $102.9 million in 2023, then increased by 22.45% to $126.0 million in 2024, then slipped by 29.45% to $88.9 million in 2025, then advanced by 29.66% to $115.2 million in 2026.
• The last three Cash & Equivalents figures came in at $115.2 million (Q1 2026), $88.9 million (Q4 2025), and $103.4 million (Q3 2025), per Business Quant data.